5 5 a r t I C l e S Extracellular Aβ deposition is a pathologic hallmark of Alzheimer's disease and a central tenet of the decades-old amyloid cascade hypothesis positing that neuronal dysfunction, synapse loss, neurofibrillary degeneration and the full manifestation of Alzheimer neuropathology is initiated by Aβ. Aβ is generated by sequential cleavage of APP by the enzymes βand γ-secretase, with BACE-1 cleavage being the rate-limiting step in this pathway 1 . Thus physical approximation of APP and BACE-1 is a required cell biological event in Aβ generation, and precise understanding of APP-BACE-1 interaction sites as well as pathways leading up to this approximation is vital.
a r t I C l e S previously established tagging strategies ( Fig. 1a ; see Online Methods and ref. 7 for details). An advantage of this assay is that complementation is irreversible, 'capturing' transient interactions, and indeed this assay has been validated for several enzyme-substrate pairs (for instance, see refs. 9,10).
First we transfected mature cultured hippocampal neurons with well-developed spines (days in vitro (DIV) 10-14, isolated from postnatal mouse pups) with APP tagged with VN and BACE-1 tagged with VC (APP:VN/BACE-1:VC) and with volume-filling mCherry, examining the cells thereafter. Fluorescence was first visible ~5 h after expression, appearing in the soma and then along processes ( Fig. 1b) . On the basis of this observation, we decided to examine our neurons ~5-6 h after APP:VN/BACE-1:VC transfection ( Fig. 1c) . At these early times the fluorescent proteins are just starting to fold and mature, and protein expression levels are at a minimum. Thus it is unlikely that conclusions based on these experiments are confounded by overexpression artifacts (also see data with the 'broken promoter' below). APP:VN/BACE-1:VC fluorescence in dendrites was punctate, resembling vesicles ( Fig. 1c) .
Several observations argue that the fluorescence read-out of the OptiCAB assay is a consequence of APP-BACE-1 interactions and not nonspecific association of the Venus fragments. The best way to determine specificity is to mutate one interacting partner in a BiFC pair and ask whether the fluorescence complementation is attenuated. To this end, we engineered an APP-fragment containing the β-cleavage site and membrane-spanning domain but lacking the C terminus, suspected to mediate APP-BACE-1 associations (called APP-STOP40; see ref . 11) . Neurons transfected with APP-STOP40: VN and BACE-1:VC were essentially nonfluorescent ( Fig. 1c) . Individually transfected VN or VC fragments were also nonfluorescent ( Fig. 1c and data not shown). These results are not due to variable expression of the transfected constructs as all tested constructs expressed adequately in neurons (Supplementary Fig. 1a ). Further data shown below (APP:VN-cleavage by BACE-1:VC and effects of Alzheimer's disease mutants) also strongly argue for the specificity of APP-BACE-1 interactions in our assay.
Does fluorescence complementation of APP:VN and BACE-1:VC lead to the cleavage of APP:VN? To address this, we cotransfected APP:VN and BACE-1:VC into cell lines, blocking γ-secretase activity with the inhibitor BMS-299897, and analyzed APP cleavage products by western blotting. If the APP:VN protein was cleaved by BACE-1: VC in these experiments, one would expect to see a cleaved APP β-C-terminal fragment (β-CTF) linked to the 17-19 kDa VN protein (β-CTF:VN), as the γ-secretase inhibitor would block further processing . 1d) . Similar results were obtained from neuro-2A cells (Fig. 1e) . Furthermore, cleavage patterns of various APP constructs also suggested that complementation does not influence β-cleavage ( Fig. 1e) , and omission of the γ-secretase inhibitor led to the expected shifts in APP cleavage ( Supplementary Fig. 1b ). Also, APP mutants linked to familial Alzheimer's disease (' Arctic' and 'London' mutations, known to enhance APP β-cleavage; see refs. 12,13) led to the expected increases in β-CTF levels in the OptiCAB assay, though total fluorescence was not enhanced in the short time frames examined (4-6 h; Supplementary Fig. 2a,b ).
APP-BACE-1 interaction sites in somatodendritic domains
Precise sites where APP and BACE-1 meet within neurons are unknown. Previous studies in non-neuronal cells or neuronal cell lines implicate a variety of locales, including the endoplasmic reticulum, Golgi, endosomes (early, late and recycling) and lysosomes 14 .
The OptiCAB assay offers an opportunity to pinpoint APP-BACE-1 interaction sites in neurons. Our general strategy was to localize WT APP-BACE-1 interaction sites unambiguously by fluorescence complementation in hippocampal neurons and determine its colocalization with established organelle markers. Somatic APP:VN/BACE-1: VC fluorescence was perinuclear, consistent with a trans-Golgi network (TGN)-type distribution. To confirm this, we cotransfected neurons with APP:VN plus BACE-1:VC, to label interaction sites, and neuropeptide Y signal sequence (NPYss), a marker that labels the interior of Golgi and Golgi-derived organelles 15, 16 . A subset of neurons was incubated at 20 °C for 2 h to block the export of proteins from the TGN (Fig. 2a) . The colocalization of complemented APP: VN/BACE-1:VC with NPYss was augmented after the temperature block ( Fig. 2b) . Furthermore, complemented APP/BACE-1 also colocalized with galactosyl transferase (GalT), a marker of TGN, confirming APP-BACE-1 interactions at this locale ( Fig. 2b,c) .
Next we focused on dendrites. Punctate structures representing APP-BACE-1 interactions were seen throughout the dendritic profiles, including shafts and spines ( Fig. 3a) . Notably, ~80% of the APP-BACE-1 complementation was seen in and around dendritic spines ( Fig. 3b) , suggesting a role for these specialized recycling microdomains in APP β-cleavage. To determine specific organelles where APP and BACE-1 interact, we cotransfected neurons with APP:VN plus BACE-1:VC and various established organelle markers (transferrin receptor (TfR) and Rab11 for recycling endosomes, Rab5 for early endosomes, LAMP-1 for late endosomes or lysosomes, and NPYss for Golgi-derived vesicles; also see ref. 7) and analyzed the neurons after ~5-6 h ( Fig. 3c) . Complemented APP/BACE-1 most conspicuously colocalized with recycling endosome markers (~60% colocalization with TfR and Rab11, as opposed to ~20-30% with other markers; Fig. 3c,d) . In previous studies, we and others found that, at steady state, neuronal BACE-1 is largely localized to recycling endosomes 7, 17 . A role for endocytosis in APP processing is well established 18 , and, on the basis of experiments evaluating the trafficking of APP and BACE-1 by live imaging, we proposed a model whereby APP undergoes endocytosis and meets BACE-1 in recycling endosomes 7 . Consistent with this model, we found that APP-BACE-1 complementation was attenuated upon inhibition of APP endocytosis-either directly, by mutation of a C-terminal APP endocytosis motif (YENPTY; see ref. 19 ), or by a global inhibition of endocytosis by the dynamin-inhibiting agent Dynasore (Fig. 3e) . These data are unlikely to be a consequence of overexpression, as an APP/BACE-1 construct driven by weakened promoters lacking enhancer elements ('broken CMV promoter'; see ref. 20) also gave similar results ( Supplementary Fig. 2c,d) .
APP-BACE-1 interaction sites in axons and presynapses
Next we studied WT APP-BACE-1 interactions in axons, examining colocalization of APP/BACE-1 BiFC with organelle markers as above ( Fig. 4a) . Fluorescent puncta representing complemented APP/BACE-1 were seen throughout the length of the axon (Fig. 4b) . However unlike dendrites, axonal APP/BACE-1 BiFC puncta largely colocalized with NPYss, a marker of Golgi-derived vesicles, and colocalization with endosomes was lower ( Fig. 4c) . Since dendritic APP/BACE-1 complementation was seen mostly in and around postsynaptic specializations where recycling occurs ( Fig. 3a) , we asked whether complementation with NPYss at 20 °C increased to 90.44 ± 2.81% from 52.68 ± 7.62% at 37 °C; *P = 0.0002, unpaired t-test, n = 11 neurons for each group from two separate sets of cultures; error bars are mean ± s.e.m. npg a r t I C l e S was also seen in presynaptic en passant boutons. The latter are major recycling sites in neurons and are mainly located along distal axons in our hippocampal cultures, where they can be easily identified by presynaptic markers 21 . To this end, we first cotransfected neurons with APP/BACE-1 and synaptophysin-mRFP, a marker for presynaptic boutons 21 . Almost all complemented APP/BACE-1 puncta colocalized with presynaptic boutons (Fig. 4d,e ). To determine the relative enrichment of APP/BACE-1 BiFC at boutons, we used a quantitative algorithm ('targeting factor') that compares levels of transfected proteins at boutons to those in the flanking axon, normalizing for potential variations in expression levels ( Fig. 4f ; also see refs. 21, 22) . Presynaptic targeting of APP/BACE-1 BiFC was npg a r t I C l e S significantly higher than that of a soluble marker, though it was, as expected, lower than that of a classic presynaptic protein, α-synuclein ( Fig. 4g,h) . These data suggest that APP and BACE-1 interact at presynaptic boutons. The physical interaction of APP and BACE-1 in axons suggests that they might also be transported by a common carrier. To test this, we first examined the axonal transport of fluorescently tagged APP and BACE-1 individually and also determined colocalization of mobile APP or BACE-1 vesicles with organelle markers (Fig. 5a,b) . Transport kinetics of APP-and BACE-1-containing vesicles were similar but not identical (Fig. 5a) , and motile particles largely colocalized with NPYss, a marker for Golgi-derived vesicles (Fig. 5b) . By contrast, colocalization of mobile axonal APP and BACE-1 vesicles with endosomal organelles was much lower ( Supplementary  Fig. 3 and Supplementary Table 1 ). Finally, we asked whether APP and BACE-1 are cotransported in axons. To this end, we cotransfected neurons with APP:GFP and BACE-1:mCherry and examined their trafficking in axons by simultaneous dual-color imaging. Most moving APP vesicles (>80%) colocalized with BACE-1, but some BACE-1 vesicles were also transported independently ( Fig. 5c) .
Collectively, the above data indicate that most APP and BACE-1 are cotransported in hippocampal axons and that the enzymesubstrate pair can interact during transit. In further support of the latter, we found that complemented APP/BACE-1 BiFC particles in axons were also mobile ( Fig. 6a,b) . Unlike axons, complemented APP/BACE-1 BiFC particles in dendrites were largely immobile in mature (DIV 14) neurons, localizing in and around spines, as noted previously (Fig. 6c) . Notably, APP/BACE-1 BiFC particles were mobile in younger (DIV 7) neurons lacking mature spines, suggesting that trafficking APP and BACE-1 can be 'captured' around dendritic spines, as shown previously for other proteins 23 . Complemented APP/BACE-1 BiFC particles at presynaptic boutons were also largely immobile, though moving particles were seen in flanking axons as expected ( Fig. 6d) .
Fate of endocytosed APP in neurons
A previous study tracked the fate of endocytosed BACE-1 in neurons, showing a remarkable retrograde bias of BACE-1-containing vesicles in dendrites 17 ; however, the fate of endocytosed WT APP in neurons is less clear. To address this, we adopted a strategy whereby membrane-spanning proteins are surface-labeled using fluorescently 24 . Specifically, we inserted a 13-aminoacid BTX-binding site at the N terminus of APP, after the APP signal sequence, to create BBS-APP; transfected neurons with BBS-APP; and then incubated the cultures with BTX-Alexa-594 (or BTX-Alexa-488) to label BBS-APP epitopes exposed to the dendritic surface ( Fig. 7a,b) . Internalized BBS-APP was seen throughout the somatodendritic compartment (Fig. 7b) . BTX-Alexa-594 internalization was specific for BBS-APP and was not seen with an APP:GFP construct that lacked the BBS domain (Fig. 7c) . Internalized APP particles were largely stationary, and mobile particles showed no directional bias (Fig. 7d) , a behavior very different from the persistent retrograde kinetics reported for internalized BACE-1 (ref. 17) .
What is the fate of endocytosed WT APP in neurons? To address this, we determined the colocalization of internalized APP with organelle markers. Neurons were transfected with BBS-APP and GFP-tagged organelle markers and incubated with BTX-Alexa-594, and colocalization of GFP with Alexa-594 was determined. In dendrites, a substantial fraction (~50%) of internalized APP vesicles were colocalized with TfR-positive recycling endosomes, while a smaller fraction (~25-30%) colocalized with Rab5 and NPYss (Fig. 7e,f) . These results are reminiscent of the APP/BACE-1 BiFC data above. Surprisingly, however, a large fraction (~70%) of internalized APP colocalized with the late endosomal or lysosomal marker LAMP-1 (Fig. 7f) . As lysosomes are not a major compartment where APP and BACE-1 interact (Fig. 3c,d) , these data suggest an alternative route for internalized APP that might limit APP-BACE-1 interactions and APP cleavage (see Discussion). Internalized APP in neuronal cell bodies was distributed as puncta throughout the soma, colocalizing with both endosomal and TGN markers (40-50%), and colocalization with LAMP-1 (~80%) was again noted (Supplementary Fig. 4) .
Reduced APP-BACE-1 interactions in a protective mutation
Recently, a search for low-frequency APP variants in whole-genome sequencing data from Icelanders revealed a mutation that confers protection against Alzheimer's disease (A673T, or the Icelandic mutation, henceforth called APP(Ice) 25 ). Although studies suggest that the APP(Ice) mutation makes APP less susceptible to BACE-1 cleavage 26, 27 , the underlying mechanism is unclear. One might imagine that this mutation alters APP trafficking pathways, perhaps rerouting the protein into aberrant organelles, diminishing its affinity for BACE-1. Alternatively, physical approximation of the mutant protein to BACE-1 may be attenuated, perhaps as a result of conformational changes in the mutant protein. To study this, we synthesized an APP:VN construct containing the Icelandic mutation (APP(Ice):VN) and transfected it with BACE-1:VC into neurons (Fig. 8a) . Fluorescence complementation was greatly attenuated (Fig. 8b,c) , despite appropriate expression of the construct (Supplementary Fig. 1) . Consequent β-cleavage of APP(Ice):VN was greatly diminished as well (Fig. 8d) . To examine trafficking parameters of the APP(Ice) protein, we determined internalization of BBS-APP(Ice) using the BBS-BTX assay described above (Supplementary Fig. 5a ). Internalization of BBS-APP(Ice) was similar to that of its WT counterpart (Supplementary Fig. 5b) . Similarly, trafficking of APP(Ice):GFP was largely unaffected ( Supplementary  Fig. 5c ). These data suggest that the protective effect of the APP(Ice) mutation may be a consequence of defective approximation of the enzyme-substrate pair before cleavage and not of altered vesicle trafficking. Finally, the OptiCAB assay also gave expected readouts in other cell types that can be easily propagated (Supplementary Fig. 6 ).
DISCUSSION
Subcellular locale of APP cleavage has been a topic of exceptional interest for decades, and yet precise sites where WT APP and BACE-1 6, 28 . Indeed, the dynamics of early and recycling endosomes in neurons is quite distinct, as we have reported previously 7 . Unlike early endosomes, recycling endosomes are much more dynamic and move with an anterograde bias in dendrites 7 . One might speculate that evolutionary demands of timely delivery into elongated processes have led to sophisticated endosomal networks in neurons that are very different from those in non-neuronal cells 32 . While studies in the latter have offered fundamental insights into the basics of APP processing, we reason that critical aspects in which neuronal pathways differ need to be appreciated as well. Finally, it is worth noting that neuronal recycling endosomes are acidic (ref. 31 and Supplementary Fig. 7) ; thus, these organelles provide a suitable milieu for BACE-1 enzymatic activity, optimal at low pH 33 .
APP-BACE-1 convergence and trafficking in axons
Our live imaging data show that WT APP and BACE-1 are cotransported in axons and that they interact in these transport vesicles ( Figs. 4  and 5) . Previous studies have shown that APP is likely processed in axons and presynaptic sites [34] [35] [36] [37] [38] . It has also been suggested that APP and BACE-1 are cotransported in a common transport carrier 39 , but this idea has been controversial [40] [41] [42] . However, arguments for or against cotransport of APP and BACE-1 have been largely based on biochemical or histological evidence, rather than direct, simultaneous visualization of the two proteins in living axons. Of note, one study did visualize axonal transport of APP or BACE-1 (separately) in axons of cultured retinal ganglion neurons, reporting much faster velocities for APP 43 . However, axonal transport of WT APP and BACE-1 was not simultaneously visualized, though qualitative data from mutant APP and BACE-1 suggested a lack of cotransport 43 .
In our studies, simultaneous visualization of WT APP and BACE-1 trafficking in hippocampal axons clearly show that APP and BACE-1 mutation. To our knowledge, these are the first data to directly show interaction of this enzyme-substrate pair in hippocampal neurons-a cell-type relevant to Alzheimer's disease-challenging long-standing models of APP and BACE-1 trafficking based on studies in nonneuronal cells and providing concrete answers to controversies.
Somatodendritic organelles where APP is cleaved by BACE-1
Previous studies in HEK293T and other cell lines show that vesicles containing APP and BACE-1 internalized from the surface colocalize with early endosomes, suggesting that these organelles are the site of β-cleavage 4,28 . These data have led to the assumption that APP β-cleavage occurs mainly in early endosomal and not biosynthetic compartments 2 . However, other studies in cell lines suggest convergence of APP and BACE-1 at the TGN and multiple endosomal compartments, including early and recycling endosomes 5, 6, 29 . Regardless, the location of APP β-cleavage in neurons, the relevant cell-type in this context, has been unknown. Our experiments in hippocampal neurons suggest that, in the soma, WT APP and BACE-1 interact at the TGN. In dendrites, WT APP and BACE-1 largely interact in recycling endosomes (~60% colocalization of APP: VN/BACE-1:VC with TfR and Rab11), with lower levels of colocalization (~20-30%) with other endosomal markers (Fig. 3) , thus implicating both biosynthetic and endosomal compartments in APP β-cleavage. Notably, about half of all APP-BACE-1 interactions were in and around dendritic spines (Fig. 3a,b) . Indeed, these microdomains are rich in recycling endosomes that recycle with the plasma membrane of the spines 30 , further supporting the concept that vesicle recycling is an important event in APP cleavage.
The collective data suggest that most steady-state WT APP-BACE-1 interactions in dendrites occur in neuronal recycling endosomes, though a transient association of APP and BACE-1 in early endosomes before their engagement in recycling compartments cannot be excluded. The potential discrepancies between data from nonneuronal cells and neurons are difficult to pinpoint, but principles governing APP trafficking in non-neuronal cells are not always applicable to neurons 1 . Neurons have an extensive network of highly dynamic and functional recycling endosomes extending throughout npg a r t I C l e S were cotransported (Fig. 5c) . Since our BiFC experiments showed that the two proteins also interact during transit, it is unlikely that they move in distinct but tandem vesicles that cannot be resolved by light microscopy. It also seems unlikely that these data are confounded by overexpression as, besides the short time-intervals after transfection (~5-6 h), overall kinetics of APP and BACE-1 were similar whether they were transfected individually or cotransfected in these neurons (Fig. 5) . Our data also indicated that APP and BACE-1 interact in presynaptic boutons (Fig. 4d-h) . The dichotomy between APP/BACE-1 trafficking in dendrites and axons is intriguing. While dendritic APP and BACE-1 largely move in distinct vesicles 7 , they are cotransported in axons. The reasons are unclear at this time, but may be related to transcytosis 32 .
Fate of internalized APP in dendrites
Though previous studies have examined internalization of APP in non-neuronal cells, the fate of internalized APP in neurons has been less clear. We used a technique whereby the intraluminal (extracellular) domain of a transmembrane protein is fluorescently tagged in live cells by surface labeling and the internalized tagged protein is then detected 24 . As predicted by our working model 7 , internalized APP colocalized with recycling endosomes in dendritic shafts; notably, however, a large fraction (~70-80%) colocalized with late endosomes or lysosomes (Fig. 7f) . APP and BACE-1 do not interact much in lysosomes (Fig. 3c,d) , and BACE-1 is also not normally localized to these compartments 7 , suggesting that routing of surface APP to late endosomes or lysosomes may be a mechanism by which APP enters the degradative pathway and escapes cleavage. This behavior is also consistent with the known short (~2 h) half-life of APP 44 . Accumulation of lysosomes in neurites and disruption of lysosomal pathways is an established pathology in Alzheimer's disease, and it is possible that such disruptions cause mislocalization of APP/BACE-1 in lysosomes, leading to enhanced cleavage in the acidic milieu. Alternatively, an intriguing possibility is that lysosomal accumulation in Alzheimer's disease is not a pathologic phenotype but an attempt by neurons to protect excess APP from cleavage. About half of the internalized APP in neuronal soma also colocalized with the TGN (Supplementary Fig. 4) , consistent with the idea that retromers and endosomal sorting complexes required for transport (ESCRT) pathways recycle endocytic APP with the Golgi 14, 29 .
APP-BACE-1 approximation in a protective mutant
A recent study showed that a point mutation of APP in Icelandic populations is protective against Alzheimer's disease 25 . Understanding the mechanistic underpinnings of this mutation might lead to new ways of targeting Alzheimer's disease pathology, and at least two scenarios can be imagined. One is that the mutation might alter trafficking of the mutant APP, perhaps partitioning it into an aberrant organelle, and diminish interaction of the enzyme-substrate pair. The other is that trafficking routes might be unaffected but approximation of the two proteins before cleavage might be attenuated. Our experiments favor the latter scenario, suggesting that the APP(Ice) mutation attenuates the association of this protein with BACE-1 (and thus APP β-cleavage), without much effect on internalization and other trafficking parameters ( Fig. 8 and Supplementary  Fig. 5 ). Recent studies also indicate that these mutations have additional effects on the aggregation properties of misfolded APP 26, 27 , suggesting multiple pathways by which this mutation protects against Alzheimer's disease. However, precise mechanisms by which the APP(Ice) mutation confers protection still remain unknown and may have to await a refined structural understanding of the underlying APP-BACE-1 interacting interface.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
